Patent: 10,118,956
✉ Email this page to a colleague
Summary for Patent: 10,118,956
Title: | Fusion partners for peptide production |
Abstract: | The present invention relates to the field of medicine, in particular, to the production of large amounts of a soluble recombinant polypeptide as part of a fusion protein comprising an N-terminal fusion partner linked to the polypeptide of interest. |
Inventor(s): | Retallack; Diane M. (Poway, CA), Chapman; Adam (San Diego, CA), Bruck; Torben R. (Lakeside, CA), Jin; Hongfan (San Diego, CA) |
Assignee: | PFENEX INC. (San Diego, CA) |
Application Number: | 14/954,766 |
Patent Claims: | see list of patent claims |
Details for Patent 10,118,956
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 06/07/2000 | ⤷ Try a Trial | 2034-12-01 |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 01/19/2001 | ⤷ Try a Trial | 2034-12-01 |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 04/23/2004 | ⤷ Try a Trial | 2034-12-01 |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 10/31/2013 | ⤷ Try a Trial | 2034-12-01 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2034-12-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |